title: An update on the current pharmacotherapy for endometrial cancer.
abstract: BACKGROUND
  Endometrial cancer (EC) is the most common gynecologic malignancy in the developed world and is increasing in incidence. While the mainstay of treatment for EC is surgery followed by chemotherapy and/or radiation therapy, the available pharmacotherapies are rapidly and constantly evolving. Understanding these new therapies is an important part of the research and clinical care of women with EC. A review of available literature from MEDLINE (1879-2015) was conducted for the historic treatments and current therapies available for endometrial tumors.
  
  
  METHODS
  This article reviews the current conventional therapies and discusses novel therapeutic agents, some of which are available to clinicians while others are currently being investigated in the preclinical setting.
  
  
  CONCLUSIONS
  Genomic and immunohistochemical characterization of endometrial cancer may soon be the best approach for the identification of aggressive forms of tumor. Targeted therapies will soon be standard in the management of endometrial cancer.
authors.affiliation: a Department of Obstetrics, Gynecology and Reproductive Sciences , Yale School of Medicine , New Haven , CT , USA.
authors.forename: Christopher
authors.initials: C
authors.lastname: de Haydu
authors.affiliation: b Department of Obstetrics, Gynecology and Reproductive Sciences, Section of Gynecologic Oncology , Yale School of Medicine , New Haven , CT , USA.
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Black
authors.affiliation: b Department of Obstetrics, Gynecology and Reproductive Sciences, Section of Gynecologic Oncology , Yale School of Medicine , New Haven , CT , USA.
authors.forename: Carlton L
authors.initials: CL
authors.lastname: Schwab
authors.affiliation: b Department of Obstetrics, Gynecology and Reproductive Sciences, Section of Gynecologic Oncology , Yale School of Medicine , New Haven , CT , USA.
authors.forename: Diana P
authors.initials: DP
authors.lastname: English
authors.affiliation: b Department of Obstetrics, Gynecology and Reproductive Sciences, Section of Gynecologic Oncology , Yale School of Medicine , New Haven , CT , USA.
authors.forename: Alessandro D
authors.initials: AD
authors.lastname: Santin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal
keywords: Adjuvant therapy; chemotherapy; endometrial cancer; endometrial pharmacotherapy; hormone therapy; targeted therapy; uterine cancer